STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
NCT: NCT07603700 · NOT_YET_RECRUITING
Brief Summary
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.
Frequently Asked Questions
What is STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism?
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism is a clinical trial registered under NCT07603700. Current status: NOT_YET_RECRUITING.
What is the status of NCT07603700?
The current status of NCT07603700 (STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism) is: NOT_YET_RECRUITING.
When did STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism start?
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism started on 2026-06-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.